ALBUREX - 25 25 %
ALBUMIN (HUMAN) : 25 % · DIN 02274663 · CSL BEHRING CANADA INC
Health Canada status: MARKETED
What is ALBUREX - 25?
ALBUREX - 25 25 % contains ALBUMIN (HUMAN) : 25 %. It is listed in the Health Canada Drug Product Database under DIN 02274663, held by CSL BEHRING CANADA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 16-Oct-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ALBUREX - 25 used for?
Alburex® 5 (5% Albumin [Human]) and Alburex® 25 (25% Albumin [Human]) are indicated for: Restoring and maintaining circulating blood volume, based on albumin’s oncotic and colloid-osmotic properties. The choice of albumin over artificial colloid and crystalloid solutions should be made according to current medical practice. SHOCK: Alburex® 5 and Alburex® 25 are indicated in the emergency treatment of shock and in other similar conditions where the restoration of blood volume is urgent. In conditions associated mainly with a volume deficit, albumin is best administered as a 5% solution; but where there is an oncotic deficit, the 25% solution may be preferred. If there has been considerable loss of red blood cells, transfusion with packed red blood cells is indicated. BURNS: Alburex® 5 and Alburex® 25 in combination with crystalloid solutions are used to maintain adequate plasma volume and protein content. HYPOPROTEINEMIA with or without edema: Alburex® 5 and Alburex® 25 are indicated in those clinical situations usually associated with a low concentration of plasma protein and a resulting decreased circulating blood volume. Measures of adequacy of circulating volume and not plasma albumin levels should be used to determine the dose required. Alburex® 5 and Alburex® 25 are not indicated as nutrient in the treatment of chronic hypoproteinemia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02274663 |
|---|---|
| Brand name | ALBUREX - 25 |
| Generic / active ingredient | ALBUMIN (HUMAN) : 25 % |
| Manufacturer | CSL BEHRING CANADA INC |
| Strength | 25 % |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Schedule D |
| ATC code | B05AA01 ALBUMIN |
| AHFS class | 16:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 16-Oct-2007 |
| Original market date | 2007-10-16 00:00:00 |
How is it stored and handled?
null
How is it supplied?
Alburex® 5 is provided as 5% (50 g/L) solution for infusion in 250 mL and 500 mL bottles, glass type II (Ph. Eur.). Alburex® 25 is provided as 25% (250 g/L) solution for infusion in 50 mL and 100 mL bottles, glass type II (Ph. Eur.).
What can be used instead?
Other Canadian products sharing ATC code B05AA01 ALBUMIN. 5 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALBUMIN (HUMAN) 25% SOLUTION USP | 25 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02223708 |
| ALBUMIN (HUMAN) 5% SOLUTION, USP | 5 % | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02223694 |
| ALBUREX - 5 | 5 % | SOLUTION | CSL BEHRING CANADA INC | MARKETED | DIN 02274655 |
| PLASBUMIN-5 | 50 MG | SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | DIN 02189100 |
| ALBUMIN (HUMAN) 25% SOLUTION | 25 % | SOLUTION | BAXTER AG | CANCELLED POST MARKET | DIN 00427659 |
| ALBUMIN (HUMAN) 5% SOLUTION | 5 % | SOLUTION | BAXTER AG | CANCELLED POST MARKET | DIN 00427675 |
| ALBUMINAR-25 | 25 G / 100 ML | SOLUTION | ZLB BEHRING LLC | CANCELLED POST MARKET | DIN 00624608 |
| ALBUTEIN 25% SOLN USP | 250 MG | SOLUTION | GRIFOLS BIOLOGICALS LLC | DORMANT | DIN 00779571 |
| ALBUTEIN 5% SOLN USP | 50 MG | SOLUTION | GRIFOLS BIOLOGICALS LLC | DORMANT | DIN 00779563 |
| BUMINATE 25% | 25 % | SOLUTION | BAXTER HEALTHCARE CORPORATION | CANCELLED POST MARKET | DIN 00118303 |
Who else supplies ALBUMIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ALBUMIN appears in 91 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.